[S(R)]-N-[(1R)-1-[2-(二苯基膦)苯基]乙基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[2-(二环己基膦)苯基](5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)甲基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[3,5-二叔丁基-4-甲氧基苯基][2-(二环己基膦)苯基]甲基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(1S)-1-[2-(二环己基膦)苯基]乙基]-N-甲基-2-叔丁基亚磺酰胺
[S(R)]-N-[(1S)-1-[2-(9-蒽基)苯基]-2-(二苯基膦)乙基]-N-甲基-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[2-(二苯基膦)苯基]苯基甲基]-N-甲基-2-叔丁基亚磺酰胺
溶解性 | DMSO ≥20mg/mL Water <1.2mg/mL Ethanol ≥11mg/mL |
存贮条件 | 储存温度 -20°C |
产品介绍 | AG14361是PARP1抑制剂,Ki<5 nM,比苯甲酰胺的抑制性强1000倍。 |
生化机理 | AG14361 is at least 1000-fold more potent than the benzamides.AG14361 treatment before irradiation statistically significantly increases the sensitivity to radiation therapy of mice bearing LoVo xenografts. AG14361 statistically significantly increases blood flow in xenografts and thus potentially increases drug delivery to tumor xenografts. |
别名 | AG 14361; 2-(4-((二甲基氨基)甲基)苯基)-5,6-二氢咪唑并(4,5,1-jk)(1,4)苯并二氮杂卓-7(4H)-酮;AG 14361; AG-14361;2-(4-((dimethylamino)methyl)phenyl)-5,6-dihydroimidazo(4,5,1-jk)(1,4)benzodiazepin-7(4h)-one; Imidazo[4,5,1-jk][1,4]benzodiazepin-7(4H)-one |